Literature DB >> 23614495

Aerosol delivery to intubated patients.

James Fink1, Arzu Ari.   

Abstract

INTRODUCTION: Approximately 20 million patients are intubated in the USA each year, primarily for the administration of drugs. While the vast majority of these medications are administered as gas or instilled, there is a growing practice of aerosol administration to intubated patients, often associated with mechanical ventilation. As no drugs have been approved for aerosol administration to intubated infants or adults, much of these practices are technically off-label. AREAS COVERED: History and advances in aerosol delivery with methods to determine delivery, with variables that impact delivery and the evolution of new technology and techniques. A literature search was undertaken using several databases including Cochrane, PubMed, Medline, Cinahl and Science Direct, covered materials from 1885 through January 2013. EXPERT OPINION: As aerosol deposition has increased with newer technologies from 1 - 3% up to 30 - 60%, there exists an opportunity to develop drugs to better treat these sickest of patients and address the current unmet medical need.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23614495     DOI: 10.1517/17425247.2013.790362

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  8 in total

Review 1.  Devices for Improved Delivery of Nebulized Pharmaceutical Aerosols to the Lungs.

Authors:  Worth Longest; Benjamin Spence; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2019-07-09       Impact factor: 2.849

2.  In Vitro Assessment of Small Charged Pharmaceutical Aerosols in a Model of a Ventilated Neonate.

Authors:  Landon Holbrook; Michael Hindle; P Worth Longest
Journal:  J Aerosol Sci       Date:  2017-05-13       Impact factor: 3.433

3.  Effects of ventilator settings, nebulizer and exhalation port position on albuterol delivery during non-invasive ventilation: an in-vitro study.

Authors:  Yuda Sutherasan; Lorenzo Ball; Pasquale Raimondo; Valentina Caratto; Elisa Sanguineti; Federico Costantino; Maurizio Ferretti; Robert M Kacmarek; Paolo Pelosi
Journal:  BMC Pulm Med       Date:  2017-01-10       Impact factor: 3.317

4.  Breath-Synchronized Nebulized Surfactant in a Porcine Model of Acute Respiratory Distress Syndrome.

Authors:  Robert M DiBlasi; Masaki Kajimoto; Jonathan A Poli; Gail Deutsch; Juergen Pfeiffer; Joseph Zimmerman; David N Crotwell; Patrik Malone; James B Fink; Coral Ringer; Rajesh Uthamanthil; Dolena Ledee; Michael A Portman
Journal:  Crit Care Explor       Date:  2021-02-15

5.  The Clinical Practice and Best Aerosol Delivery Location in Intubated and Mechanically Ventilated Patients: A Randomized Clinical Trial.

Authors:  Chuanlin Zhang; Jie Mi; Zeju Zhang; Xueqin Wang; Yunxiao Zhu; Xinyi Luo; Ruiying Gan; Xiaoya Chen; Yujun Zou
Journal:  Biomed Res Int       Date:  2021-04-03       Impact factor: 3.411

6.  Effect of IFN-α and other commonly used nebulization drugs in different nebulization methods on the resistance of breathing circuit filters under invasive mechanical ventilation.

Authors:  Zhenjie Jiang; Hanwen Liang; Guixia Peng; Shiya Wang; Baozhu Zhang; Qingwen Sun; Yuanda Xu; Huiqing Zeng; Jingye Huang
Journal:  Ann Transl Med       Date:  2022-02

7.  Initial Development of an Air-Jet Dry Powder Inhaler for Rapid Delivery of Pharmaceutical Aerosols to Infants.

Authors:  Connor Howe; Michael Hindle; Serena Bonasera; Vijaya Rani; P Worth Longest
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2020-08-04       Impact factor: 2.849

8.  Preventive nebulization of mucolytic agents and bronchodilating drugs in invasively ventilated intensive care unit patients (NEBULAE): study protocol for a randomized controlled trial.

Authors:  Sophia M van der Hoeven; Jan M Binnekade; Corianne A J M de Borgie; Frank H Bosch; Henrik Endeman; Janneke Horn; Nicole P Juffermans; Nardo J M van der Meer; Maruschka P Merkus; Hazra S Moeniralam; Bart van Silfhout; Mathilde Slabbekoorn; Willemke Stilma; Jan Willem Wijnhoven; Marcus J Schultz; Frederique Paulus
Journal:  Trials       Date:  2015-09-02       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.